» Articles » PMID: 20308386

Intra- and Extracellular Activities of Dicloxacillin Against Staphylococcus Aureus in Vivo and in Vitro

Overview
Specialty Pharmacology
Date 2010 Mar 24
PMID 20308386
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic treatment of Staphylococcus aureus infections is often problematic due to the slow response and recurrences. The intracellular persistence of the staphylococci offers a plausible explanation for the treatment difficulties because of the impaired intracellular efficacies of the antibiotics. The intra- and extracellular time- and concentration-kill relationships were examined in vitro with THP-1 cells and in vivo by use of a mouse peritonitis model. The in vivo model was further used to estimate the most predictive pharmacokinetic/pharmacodynamic (PK/PD) indices (the ratio of the maximum concentration of drug in plasma/MIC, the ratio of the area under the concentration-time curve/MIC, or the cumulative percentage of a 24-h period that the free [f] drug concentration exceeded the MIC under steady-state pharmacokinetic conditions [fT(MIC)]) for dicloxacillin (DCX) intra- and extracellularly. In general, DCX was found to have similar intracellular activities, regardless of the model used. Both models showed (i) the relative maximal efficacy (1-log-unit reduction in the numbers of CFU) of DCX intracellularly and (ii) the equal relative potency of DCX intra- and extracellularly, with the MIC being a good indicator of the overall response in both situations. Discordant results, based on data obtained different times after dosing, were obtained from the two models when the extracellular activity of DCX was measured, in which the in vitro model showed a considerable reduction in the number of CFU from that in the original inoculum (3-log-unit decrease in the number of CFU after 24 h), whereas the extracellular CFU reduction achieved in vivo after 4 h did not exceed 1 log unit. Multiple dosing of DCX in vivo revealed increased extra- and intracellular efficacies (2.5 log and 2 log units of reduction in the numbers of CFU after 24 h, respectively), confirming that DCX is a highly active antistaphylococcal antibiotic. PK/PD analysis revealed that fT(MIC) is the index that is the most predictive of the outcome of infection both intra- and extracellularly.

Citing Articles

Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an Model of Intracellular Infection.

Kerkez I, Tulkens P, Tenson T, Van Bambeke F, Putrins M Antimicrob Agents Chemother. 2021; 65(12):e0146821.

PMID: 34570646 PMC: 8597737. DOI: 10.1128/AAC.01468-21.


Development of Antimicrobial Phototreatment Tolerance: Why the Methodology Matters.

Rapacka-Zdonczyk A, Wozniak A, Nakonieczna J, Grinholc M Int J Mol Sci. 2021; 22(4).

PMID: 33672375 PMC: 7926562. DOI: 10.3390/ijms22042224.


Ginger (Zingiber officinale) phytochemicals-gingerenone-A and shogaol inhibit SaHPPK: molecular docking, molecular dynamics simulations and in vitro approaches.

Rampogu S, Baek A, Gajula R, Zeb A, Bavi R, Kumar R Ann Clin Microbiol Antimicrob. 2018; 17(1):16.

PMID: 29609660 PMC: 5879566. DOI: 10.1186/s12941-018-0266-9.


Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo.

Wang X, Wang X, Teng D, Mao R, Hao Y, Yang N Sci Rep. 2018; 8(1):4204.

PMID: 29523806 PMC: 5844868. DOI: 10.1038/s41598-018-22245-5.


Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Stage T, Graff M, Wong S, Rasmussen L, Nielsen F, Pottegard A Br J Clin Pharmacol. 2017; 84(3):510-519.

PMID: 29105855 PMC: 5809358. DOI: 10.1111/bcp.13467.


References
1.
Sanabria T, Alpert J, Goldberg R, Pape L, Cheeseman S . Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. Arch Intern Med. 1990; 150(6):1305-9. View

2.
Frimodt-Moller N, Rosdahl V, Sorensen G, Hartzen S, Bentzon M . Relationship between penicillinase production and the in-vitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase.... J Antimicrob Chemother. 1986; 18(1):27-33. DOI: 10.1093/jac/18.1.27. View

3.
Barcia-Macay M, Seral C, Mingeot-Leclercq M, Tulkens P, Van Bambeke F . Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006; 50(3):841-51. PMC: 1426441. DOI: 10.1128/AAC.50.3.841-851.2006. View

4.
Lowy F . Staphylococcus aureus infections. N Engl J Med. 1998; 339(8):520-32. DOI: 10.1056/NEJM199808203390806. View

5.
Hess D, Henry-Stanley M, Erickson E, Wells C . Intracellular survival of Staphylococcus aureus within cultured enterocytes. J Surg Res. 2003; 114(1):42-9. DOI: 10.1016/s0022-4804(03)00314-7. View